Pharmaceutical formulation comprising pramipexole
AssigneeBoehringer Ingelheim International GmbH
InventorsJuergen Reess, Thomas Friedl, Nantharat Pearnchob
Life of this patent
Estimating the term…
Abstract
The present invention refers to the use of a medicament for the paediatric treatment of RLS and/or Tic Disorder and/or Tourette's Syndrom.
Claims17
A method for treating RLS in a child, comprising administering to a child suffering from RLS a per day dosage of pramipexole dihydrochloride monohydrate between 0.01 mg and 0.75 mg.
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating RLS in a child, comprising administering to a child suffering from RLS a pharmaceutical formulation comprising pramipexole free base or a pramipexole salt form in an amount that corresponds to 0.06 mg to 0.09 mg of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole.
(canceled)
(canceled)
(canceled)
A method for treating RLS in a child, comprising administering to a child suffering from RLS a pharmaceutical formulation comprising pramipexole free base or a pramipexole salt form in an amount that corresponds to 0.03 mg to 0.05 mg of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole.
A method for treating RLS in a child, comprising administering to a child suffering from RLS a pharmaceutical formulation comprising pramipexole free base or a pramipexole salt form in an amount that corresponds to 0.01 mg to 0.029 mg of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole.
Dependencies are inferred from the claim text.